FDA Withdraws Firm’s Approval Of Drug Touted As Autism Therapy

U.S. regulators have withdrawn their approval of a GSK Plc drug that the Trump administration had promoted as a remedy for autism, including one other twist to the bizarre story of a decades-old drug.

The Meals and Drug Administration is pulling its approval of Wellcovorin, a branded model of leucovorin from GSK Plc, based on a publish Thursday within the Federal Register. GSK had requested that the approval be withdrawn, the publish stated.

The FDA first permitted leucovorin many years in the past and it’s been used to blunt the unintended effects of chemotherapy for some most cancers sufferers. In September, Trump administration officers endorsed the usage of leucovorin as an autism remedy. Final month, the FDA permitted its use for cerebral folate deficiency, which is seen in some individuals with autism.

GSK held the patent for Wellcovorin. On the FDA’s request, the corporate stated in September it will search approval to be used of the drug for sufferers with cerebral folate deficiency. GSK’s approval was a procedural step essential to make the generic model of the drug accessible.

By asking the FDA to withdraw Wellcovorin’s approval for cerebral folate deficiency, GSK will not have the ability to promote it for that use. The generic model remains to be accessible to cerebral folate deficiency sufferers, the FDA stated.

A FDA spokesperson stated GSK’s motion “doesn’t have an effect on the provision of generic leucovorin for sufferers with CFD, or the labeling of leucovorin merchandise.”

GSK doesn’t make or promote Wellcovorin, or the generic equal.

“The label adjustments made to Wellcovorin will assist allow generics already on market so as to add this new indication to their labelling,” GSK stated in a press release Thursday.

With help from Rachel Cohrs Zhang and Madison Muller.

© 2026 Bloomberg L.P.
Distributed by Tribune Content material Company, LLC